USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: SENEX BIOTECHNOLOGY, INC.
Address: 715 Sumter Street
Columbia, SC 29208-
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $314,001.00 3
SBIR Phase II $2,350,603.00 2

Award List:

Inhibitors of disease-promoting activities of senescence

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Donald C. Porter
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): The proposed project is aimed at developing a novel class of drugs against chronic diseases associated with old age. Such agents act by inhibiting a newly discovered regulatory pathway that endows senescent cells with disease- promoting paracrine activities.… More

Small Molecules Inducing BTG1 Transcription

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $107,001.00
Abstract:
DESCRIPTION (provided by applicant): BTG1 is a transcription regulatory protein that interacts with different transcription factors and nuclear receptors. BTG1 acts as a tumor suppressor and as a mediator of myogenic and erythroid differentiation. BTG1 tra nscription is positively regulated by… More

Inhibitors of disease-promoting activities of senescence

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $802,501.00
Abstract:
DESCRIPTION (provided by applicant): This project is aimed at developing a new class of drugs, which act by inhibiting pathogenic activities of senescent cells. Cell senescence occurring as a result of aging or cellular damage, is associated with upregulat ion and secretion of proteins implicated in… More

CDK3-inhibiting anticancer agents

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Donald C. Porter
Award Amount: $107,000.00
Abstract:
DESCRIPTION (provided by applicant): This Phase I SBIR project is aimed at developing a novel type of anticancer drugs, termed SNX9- class compounds. These compounds have a dual activity: (i) inhibition of a transcriptional regulatory pathway that endows g rowth-arrested tumor cells and… More

CDK3-inhibiting anticancer agents

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Donald C. Porter – 803-777-6161
Award Amount: $1,548,102.00
Abstract:
DESCRIPTION (provided by applicant): This Phase II SBIR project is aimed at developing a novel type of drugs, termed SNX9-class compounds, with a unique combination of two anticancer activities. The first is a selective antiproliferative effect on tumor cells relative to normal cells. The second is… More